Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

e 30, of U.S.$) 2009 2008 2009 2008 -------------------- --------------------------- ------------------------ Net (loss) income on a GAAP basis $ (11,877) (26,071) $ 567 $ (41,834) Interest expense on long-term debt 9,641 10,941 19,685 23,061 Income tax (recovery) expense (217) (1,988) 5,507 (5,802) Depreciation and amortization 9,207 9,723 18,368 19,172 -------------------- --------------------------- ------------------------ EBITDA 6,754 (7,395) 44,127 (5,403) Adjustments: Non-recurring revenue, net of license fees (398) (53) (25,451) (106) Abnormal manufacturing variances and inventory write-downs 896 - 896 - In-process research and development - - - 2,500 Non-recurring research and development 625 - 938 625 Stock-based compensation 423 607 807 1,425 Litigation expenses 1,494 691 2,241 2,289 Foreign exchange loss (gain) 1,441 (140) 709 (563) Investment and other income 600 (686) 615 (1,442) Severance and restructuring 332 1,762 1,266 4,840 Write off of capitalized costs - 500 - 500 Write-down / loss on redemption of investments - 10,660 - 10,660 Non-recurring financing costs 413 - 1,032 - --
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: ... develops and commercializes proprietary technologies and products for ... has received approval from the TSX Venture Exchange ... share purchase warrants ("the Warrants") of the Company, ... May 2013 private placement financing. Each ...
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2
... Antidepressant Can Help Adults Living With ... Relief -(1), PRINCETON, N.J. and TOKYO, Nov. ... and Otsuka Pharmaceutical Co.,Ltd. announced today that the ... New Drug Application for ABILIFY(R),(aripiprazole) as adjunctive, or ...
... BB: CLBE), an emerging life sciences company ( http://www.CalbaTech.com ... stem cells for,possible future therapeutic uses and providing products ... to academic,institutions, said today in its 10Q filing with ... be profitable in 2007. The addition of sales ...
... will present at the Piper Jaffray 19th Annual Healthcare ... Pierre Hotel in New York. John L.,Bishop, Chief Executive ... Chief Financial Officer, will provide a corporate overview. ... be,accessed on Cepheid,s Web site at http://www.cepheid.com ...
Cached Biology Technology:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 9CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 2CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 3Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Wistar Institute have deciphered the structure of the active ... role in the development of nearly all human cancers. ... of new, broadly effective cancer drugs, as well as ... a decade to find drugs that shut down telomerasewidely ...
... have long known to be related to each other women ... Now, a master switch has been found in the brain of ... Biological Studies say it may work the same way in humans. ... Aug. 31 online edition of Nature Medicine , suggest that ...
... was reached by the Alliance for a Healthier Generation ... on "competitive foods" such as soft drinks at schools. ... the availability of soft drinks at school may not ... children. In a study of more than 4,000 ...
Cached Biology News:Landmark study opens door to new cancer, aging treatments 2Landmark study opens door to new cancer, aging treatments 3New master switch found in the brain that regulates appetite and reproduction 2New master switch found in the brain that regulates appetite and reproduction 3New master switch found in the brain that regulates appetite and reproduction 4
... Topo I, Wild Type ... Tris-HCl, 1 mM DTT, 200 µM EDTA, 20% ... topoisomerase I (Topo I) is a monomeric protein ... gene. It catalyzes the relaxation of both positive ...
RNase-Free DNase 50 l...
Request Info...
... is a DNA-dependent RNA polymerase which is ... It efficiently synthesizes in vitro transcripts from ... from a T7 promoter. Transcripts can ... in vitro translation, substrates in RNA processing ...
Biology Products: